MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 100730 | Name: Pipobroman
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pipobroman (trade names Vercite, Vercyte) is an anti-cancer drug that probably acts as an alkylating agent. It is marketed by Abbott Laboratories. Pipobroman (PB) has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET).

Chemical Structure

Pipobroman
Pipobroman
CAS#54-91-1

Theoretical Analysis

MedKoo Cat#: 100730

Name: Pipobroman

CAS#: 54-91-1

Chemical Formula: C10H16Br2N2O2

Exact Mass: 353.9579

Molecular Weight: 356.06

Elemental Analysis: C, 33.73; H, 4.53; Br, 44.88; N, 7.87; O, 8.99

Price and Availability

Size Price Availability Quantity
200mg USD 250.00 2 Weeks
500mg USD 550.00 2 Weeks
1g USD 850.00 2 Weeks
2g USD 1,550.00 2 Weeks
5g USD 3,450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
NSC25154; Pipobroman; Trade names Vercite Vercyte.
IUPAC/Chemical Name
1,1'-(piperazine-1,4-diyl)bis(3-bromopropan-1-one)
InChi Key
NJBFOOCLYDNZJN-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H16Br2N2O2/c11-3-1-9(15)13-5-7-14(8-6-13)10(16)2-4-12/h1-8H2
SMILES Code
O=C(N1CCN(C(CCBr)=O)CC1)CCBr
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Pipobroman was approved in German. Pipobroman is an antineoplastic agent. Specifically it is a piperazine derivative with a chemical structure close to that of many DNA alkylating agents. Pipobroman has well documented clinical activity against polycythemia vera and essential thrombocythemia. According to drugbank, pipobroman was indicated for the treatment of polycythaemia vera and refractory chronic myeloid leukaemia.   The mechanism of action is uncertain but pipobroman is thought to alkylate DNA leading to disruption of DNA synthesis and eventual cell death.    
Biological target:
Pipobroman is a bromide derivative of piperazine and acts as an alkylating agent.
In vitro activity:
TBD
In vivo activity:
TBD
Solvent mg/mL mM comments
Solubility
DMSO 53.5 150.26
Ethanol 71.0 199.41
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 356.06 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Ann Hematol. 2024 Jul;103(7):2299-2310. doi: 10.1007/s00277-024-05665-4. Epub 2024 Mar 4. PMID: 38438627; PMCID: PMC11224110. 2: Passamonti F, Palandri F, Saydam G, Callum J, Devos T, Guglielmelli P, Vannucchi AM, Zor E, Zuurman M, Gilotti G, Zhang Y, Griesshammer M. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Lancet Haematol. 2022 Jul;9(7):e480-e492. doi: 10.1016/S2352-3026(22)00102-8. Epub 2022 May 18. PMID: 35597252. 3: Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020 Mar;7(3):e226-e237. doi: 10.1016/S2352-3026(19)30207-8. Epub 2020 Jan 23. PMID: 31982039; PMCID: PMC8938906. 4: Jiang YL, Broome AM. Novel Pyrene Excimer and Fluorogenic Probe for the Detection of Alkylating Agents. ACS Sens. 2019 Jul 26;4(7):1791-1797. doi: 10.1021/acssensors.9b00274. Epub 2019 Jul 12. PMID: 31299153. 5: Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia. 2019 Aug;33(8):1996-2005. doi: 10.1038/s41375-019-0487-8. Epub 2019 May 29. PMID: 31142846. 6: Andriani A, Elli E, Trapè G, Villivà N, Fianchi L, Di Veroli A, Niscola P, Centra A, Anaclerico B, Montanaro G, Martini V, Aroldi A, Carmosino I, Voso MT, Breccia M, Montanaro M, Foà R, Latagliata R. Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. Hematol Oncol. 2019 Aug;37(3):291-295. doi: 10.1002/hon.2635. Epub 2019 May 30. PMID: 31050810. 7: Cuthbert D, Stein BL. Therapy-associated leukemic transformation in myeloproliferative neoplasms - What do we know? Best Pract Res Clin Haematol. 2019 Mar;32(1):65-73. doi: 10.1016/j.beha.2019.02.004. Epub 2019 Feb 8. PMID: 30927977. 8: Abruzzese E, Trawinska MM, Neri B, Bondanini F, Fratoni S, Tendas A, Scaramucci L, Siniscalchi A, Giovannini M, Palumbo R, de Fabritiis P, Niscola P. Successful Decitabine Treatment in Unfit, Elderly Patients with Acute Myeloid Leukemia following Chronic Myeloproliferative Neoplasm. Acta Haematol. 2018;140(4):231-233. doi: 10.1159/000493880. Epub 2018 Nov 1. PMID: 30384359. 9: Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019 Jan;94(1):133-143. doi: 10.1002/ajh.25303. Epub 2018 Nov 9. PMID: 30281843. 10: Yogarajah M, Tefferi A. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome. Mayo Clin Proc. 2017 Jul;92(7):1118-1128. doi: 10.1016/j.mayocp.2017.05.010. PMID: 28688466. 11: Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7. Epub 2016 Dec 2. PMID: 27916398. 12: Nazha A, Gerds AT. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera? Oncologist. 2016 Apr;21(4):475-80. doi: 10.1634/theoncologist.2015-0380. Epub 2016 Mar 14. PMID: 26975864; PMCID: PMC4828120. 13: Cassius C, Pages C, Roux J, Lhote R, Lavocat R, Réa D, Bagot M, Mourah S, Battistella M, Lebbé C, Dumaz N. Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma. J Invest Dermatol. 2016 Jun;136(6):1302-1305. doi: 10.1016/j.jid.2015.12.047. Epub 2016 Feb 15. PMID: 26854489. 14: Pathak RK, Dhar S. Unique Use of Alkylation for Chemo-Redox Activity by a Pt(IV) Prodrug. Chemistry. 2016 Feb 24;22(9):3029-36. doi: 10.1002/chem.201503866. Epub 2016 Jan 25. PMID: 26807548. 15: Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015 Nov 13;5(11):e366. doi: 10.1038/bcj.2015.95. PMID: 26565403; PMCID: PMC4670948. 16: Stein BL, Moliterno AR, Tiu RV. Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. Ann Hematol. 2014 Dec;93(12):1965-76. doi: 10.1007/s00277-014-2205-y. Epub 2014 Oct 2. PMID: 25270596. 17: Sever M, Newberry KJ, Verstovsek S. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. Leuk Lymphoma. 2014 Dec;55(12):2685-90. doi: 10.3109/10428194.2014.893310. Epub 2014 Mar 17. PMID: 24524340; PMCID: PMC4835800. 18: Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013 Sep;27(9):1874-81. doi: 10.1038/leu.2013.163. Epub 2013 Jun 6. PMID: 23739289; PMCID: PMC3768558. 19: Fazio G, Caracciolo C, Barone R, D'angelo L, Di Maggio R, Vernuccio F, Siragusa S. An unknown cause of aortic valve stenosis: polycythemia vera. J Thromb Thrombolysis. 2013 Feb;35(2):282-5. doi: 10.1007/s11239-012-0786-7. PMID: 22843194. 20: Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011 Oct 10;29(29):3907-13. doi: 10.1200/JCO.2011.36.0792. Epub 2011 Sep 12. PMID: 21911721.